Veradermics Announces Pricing of Upsized IPO

Got story updates? Submit your updates here. ›

Veradermics, a late-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, has announced the pricing of its upsized initial public offering of 15,077,647 shares of common stock at $17 per share. The company expects to raise approximately $256.3 million in gross proceeds from the offering, which is expected to close on February 5, 2026.

Why it matters

Veradermics' public debut marks a significant milestone for the company as it seeks to advance its pipeline of dermatology and aesthetic medicine products, including its lead program VDPHL01, an oral treatment for pattern hair loss. The successful IPO provides Veradermics with additional capital to fund its research and development efforts as it looks to address unmet needs in the dermatology space.

The details

The IPO was upsized from the original offering size, indicating strong investor demand. Veradermics' common stock is expected to begin trading on the New York Stock Exchange under the ticker symbol 'MANE'. Jefferies, Leerink Partners, Citigroup, and Cantor are serving as joint book-running managers for the offering.

• Veradermics' common stock is expected to begin trading on the New York Stock Exchange on February 4, 2026.
• The offering is expected to close on February 5, 2026, subject to the satisfaction of customary closing conditions.

What’s next

Veradermics' common stock is expected to begin trading on the New York Stock Exchange on February 4, 2026, and the offering is expected to close on February 5, 2026, subject to the satisfaction of customary closing conditions.